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S U M M A R Y
Background: Bartonella henselae, Bartonella quintana, and Bartonella bacilliformis are responsible for the
majority of cases of bartonellosis in humans. These species have various unique epidemiologic
characteristics, clinical manifestations, and treatment approaches. The objective of this study was to
summarize the evidence on the treatment for the three most common species of Bartonella in humans.
Methods: We searched electronic databases through August 2011 for randomized controlled trials and
observational studies designed to evaluate the efﬁcacy and safety of the regimens used to treat diseases
produced by B. henselae, B. quintana, and B. bacilliformis. Study selection and appraisal were done in
duplicate.
Results: We found two randomized and seven non-randomized studies at high risk of bias. For cat
scratch disease, antibiotics did not signiﬁcantly affect the cure rate or time to achieve cure. In chronic
bacteremia, gentamicin and doxycycline signiﬁcantly increased the resolution rate. The recommended
treatment was not better than other regimens for infectious endocarditis and bacillary angiomatosis.
Conclusions: Current clinical practice for the treatment of bartonellosis relies mostly on expert opinion
and antimicrobial susceptibility data. Randomized controlled trials are needed in the ﬁeld to compare
different treatment options.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Contents lists available at SciVerse ScienceDirect
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Three species of Bartonella are responsible for the vast majority
of infections in humans: B. henselae, B. quintana, and B. bacilliformis.
Each one of these species leads to different clinical manifestations
and requires different treatment approaches.1,2While the infection
caused by B. henselae has a worldwide distribution,3 with an
incidence of 3.7 per 100 000 (according to a study from the USA),4
B. quintana and B. bacilliformis cases are geographically and
demographically limited. B. quintana has predominantly involved
homeless persons with head or body lice exposure in Europe and
the USA.5 Its incidence is unclear, as only a small portion of the* Corresponding author. Tel.: +1 507 266 1846.
E-mail address: prutskylopez.gabriela@mayo.edu (G. Prutsky).
1201-9712/$36.00 – see front matter  2013 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2013.02.016infected population will develop overt clinical disease.5,6 On the
other hand, B. bacilliformis is restricted to certain mountain regions
of Peru, Ecuador, and Colombia, known as the ‘verruge zone’,7
having an incidence in the general population of 2.7 cases of
bartonellosis (either Oroya fever, verruga peruana, or asymptom-
atic infection) per 100 person-years.8
In immunocompetent patients, B. henselae can cause an acute
infection called cat scratch disease (CSD), which usually manifests
as subacute, regional lymphadenopathy. Likewise, infection
caused by B. bacilliformis can manifest as an acute phase called
Oroya fever or as a chronic phase in Oroya fever survivors called
verruga peruana. The acute and chronic states of B. quintana
infection are trench fever and chronic bacteremia, respectively.9,10
When the affected patients are immunocompromised subjects,
mainly but not limited to HIV patients, Bartonella species can
produce a broad array of manifestations, including bacillaryses. Published by Elsevier Ltd. All rights reserved.
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teremia.11,12
Bartonella infections present a unique challenge for several
reasons, including the high mortality of infected humans who do
not receive treatment in the case of B. bacilliformis acute
infection,13,14 and the persistence and frequent relapses due to
the existence of an intraerythrocytic phase that may provide a
protective niche for the bacteria.15
Current recommendations for the choice, route, and extent of
an antimicrobial treatment for infections caused by Bartonella spp
are made depending on the infective species, the clinical course,
and the immunological state of the patient. They are mainly based
on nonsystematic clinical observations and expert panel consensus
statements.16–18 Unfortunately these approaches are limited by
deﬁciencies in the human process of making inferences.19
No systematic reviews have been done to summarize and
appraise the evidence informing the treatment decisions for
infections caused by Bartonella spp. We believe that by gathering
and analyzing the current evidence concerning the therapeutics of
Bartonella infections, we may be able to draw evidence-based
conclusions or, in the lack of it, incite future development of
evidence-based knowledge concerning this important infection.
Therefore, we conducted this systematic review to inform current
treatment decisions and future research activities.
2. Methods
Search and analysis methods, eligibility criteria, and the
outcomes of interest were speciﬁed in advance in a protocol
developed by the study investigators.
2.1. Eligibility criteria
We included randomized controlled trials (RCTs) and observa-
tional studies that enrolled patients of any age and gender,
designed to evaluate the efﬁcacy and safety of the different
regimens used to treat diseases produced by the three most
common species of human Bartonella (Table 1).
2.2. Search methods
An expert reference librarian (PJE) designed and conducted an
electronic search strategy following the protocol (Table 2). We
searched electronic databases to identify relevant studies (Ovid
Medline, Ovid EMBASE, Ovid Cochrane Library, Web of Science,
Scopus, PsycInfo, and CINAHL) from their inception through
August 2011. To identify additional candidate studies, we reviewed
the reference lists of the eligible primary studies, narrative
reviews, and systematic reviews. We also contacted experts onTable 1
Diseases produced by the most common species of human Bartonella.
Bartonella henselae:
Cat scratch disease (CSD)
Bacillary angiomatosis
Peliosis hepatis
Infectious endocarditis
Chronic bacteremia
Bartonella quintana:
Bacillary angiomatosis
Trench fever
Infectious endocarditis
Chronic bacteremia
Bartonella bacilliformis:
Carrion disease
Acute phase
Chronic phasethe topic for this purpose and performed a manual search for
unpublished studies or studies published in non-indexed journals
(1. The Brazilian Journal of Infectious Diseases, 2. Revista Medica
Herediana, 3. Diagno´stico, 4. Folia Dermatolo´gica Peruana, 5.
Revista del Instituto de Medicina Tropical de Sao Paulo, 6. Acta
Medica Peruana, 7. Revista Peruana de Enfermedades Infecciosas y
Tropicales, 8. CID (Clinical Infectious Diseases), 9. Revista de
Gastroenterologı´a del Peru´, 10. Revista de Neuro-Psiquiatrı´a).
2.3. Selection of studies
Two reviewers working independently considered the potential
eligibility of each of the abstracts and titles that resulted from
executing the search strategy. Eligible studies were reviewed in full
text versions (all available versions of each study). There were no
disagreements between the reviewers in the full text screening.
2.4. Data extraction and management
Using a standardized, piloted, and web-based data extraction
form and working in duplicate, we abstracted the following
descriptive data from each study: full description of participants
enrolled (age, diagnosis criteria, severity), interventions they
received (type, frequency, and route), control interventions,
monitoring methods for efﬁcacy of the follow-up and adherence
to the treatment, measures of outcome (speciﬁcally deﬁned as
event or measure and time frame for the ascertainment of this
outcome), and source of funding. We extracted the outcomes of
interest at the longest point of complete follow-up.
2.5. Outcomes of interest
After the screening process, we extracted the following
outcomes from the included studies: clinical cure or response to
therapy, death rate, superimposed infectious disease, time to
achieve clinical cure, severe adverse effects (deﬁned as any drug
effect that was strong enough to force the patient to stop the
treatment, grade 2–420), and relapse rates.
2.6. Author contact
When data were not available from the published papers,
repeated efforts were made to contact the authors. We decided a
priori to e-mail the authors twice, 2 weeks apart, and to use mail
when an e-mail address was not available.
2.7. Assessment of the risk of bias in included studies
To assess the methodological quality of the included RCTs we
used the Cochrane risk of bias assessment tool to evaluate:
randomization performance and methods, allocation concealment,
baseline imbalances, extent of blinding (patients, caregivers, data
collectors, outcome assessors, and data analysts), rate of loss to
follow-up, and whether adherence was monitored. For observa-
tional studies we used the Newcastle–Ottawa quality assessment
tool to evaluate how the groups were selected, the comparability
between them, whether there was adequate follow-up, and how
the outcomes and exposure were ascertained.
2.8. Meta-analysis
For dichotomous outcomes we estimated the odds ratio (OR)
and for continuous outcomes we estimated the weighted mean
difference (WMD). The I2 statistic was used to measure inconsis-
tency in results across studies not attributable to chance.21 To pool
data across studies, we tested a random effects model and a ﬁxed
Table 2
Search strategy
Ovid
Database(s): EMBASE 1988 to 2011 week 25; Ovid MEDLINE in-process and other non-indexed citations and Ovid MEDLINE 1948 to present, EBM Reviews – Cochrane
Central Register of Controlled Trials 2nd Quarter 2011, EBM Reviews – Cochrane Database of Systematic Reviews 2005 to June 2011
# Searches Results
1 exp Anti-Bacterial Agents/ 1 841 773
2 exp antibiotic agent/ 587 440
3 ((antibiotic* or ‘‘anti-biotic*’’ or (antimycobacterial or ‘‘anti-mycobacterial’’ or antibacterial
or ‘‘anti-bacterial’’ or bacteriocidal)) adj (agent or agents)).mp. [mp=ti, ab,
sh, hw, tn, ot, dm, mf, dv, kw, ps, rs, nm, ui, tx, ct]
370 688
4 or/1–3 1 845 395
5 exp Bartonella Infections/dt [Drug Therapy] 879
6 (((bartonellosis or (bartonella or rochalimaea or bartonellaceae)) adj2
(infection* or bacteremia)) or ‘‘cat scratch fever*’’ or ‘‘oroya fever*’’ or
(carrion* adj disease) or ‘‘verruga peruana’’ or ‘‘bacillary angiomatosis’’
or ‘‘trench fever’’).mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, ps, rs, nm, ui, tx, ct]
2817
7 5 or (4 and 6) 1269
8 exp controlled study/ 3 551 676
9 exp evidence based medicine/ 495 377
10 evidence-based.mp. 166 460
11 ((control$ or randomized) adj2 (study or studies or trial or trials)).mp.
[mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, ps, rs, nm, ui, tx, ct]
4 545 775
12 meta analysis/ 83 178
13 meta-analys$.mp. 131 591
14 exp ‘‘systematic review’’/ 41 492
15 systematic review$.mp. 91 862
16 exp Guideline/or exp Practice Guideline/ 263 122
17 guideline$.ti. 83 824
18 or/8–17 5 042 389
19 exp Cohort Studies/ 1 285 714
20 exp longitudinal study/ 854 104
21 exp retrospective study/ 600 779
22 exp prospective study/ 512 155
23 exp observational study/ 20 881
24 exp comparative study/ 2145971
25 exp clinical trial/ 1 442 390
26 exp evaluation/ 1 056 005
27 exp validation study/ 25 379
28 ((clinical or evaluation or validation or pilot or comparative or cohort or
longitudinal or retrospective or prospective or concurrent or follow-up or
observational) adj (study or studies or analysis or analyses or trial or trials)).mp.
6 276 418
29 or/19–28 6 882 063
30 7 and (18 or 29) 199
31 from 7 keep 828–1267 440
32 limit 31 to (clinical trial, all or clinical trial, phase i or clinical trial, phase ii
or clinical trial, phase iii or clinical trial, phase iv or clinical trial or comparative
study or controlled clinical trial or evaluation studies or guideline or meta analysis
or multicenter study or practice guideline or randomized controlled trial
or validation studies) [Limit not valid in EMBASE, CCTR, CDSR; records were retained]
13
33 from 7 keep 1268–1269 2
34 30 or 32 or 33 199
35 limit 34 to human [Limit not valid in CCTR, CDSR; records were retained] 181
36 limit 35 to humans [Limit not valid in CCTR, CDSR; records were retained] 181
37 limit 36 to (book or book series or editorial or erratum or letter or addresses or autobiography
or bibliography or biography or comment or dictionary or directory or interactive tutorial or
interview or lectures or legislation or news or newspaper article or patient education handout or
periodical index or portraits or published erratum or video-audio media or webcasts)
[Limit not valid in EMBASE, Ovid MEDLINE, Ovid MEDLINE In-Process, CCTR, CDSR; records were retained]
9
38 36 not 37 172
39 remove duplicates from 38 148
Scopus
1 TITLE-ABS-KEY(bartonellosis or (bartonella w/2 infection*) or (rochalimaea w/2 infection*) or (bartonellaceae w/2 infection*) or (bartonella w/2 bacteremia) or
(rochalimaea w/2 bacteremia) or (bartonellaceae w/2 bacteremia) or ‘‘cat scratch fever*’’ or ‘‘oroya fever*’’ or (carrion* w/1 disease) or ‘‘verruga peruana’’ or
‘‘bacillary angiomatosis’’ or ‘‘trench fever’’)
2 TITLE-ABS-KEY(antibiotic* or ‘‘anti-biotic*’’ or (antimycobacterial w/1 agent) or (‘‘anti-mycobacterial’’ w/1 agent) or (antibacterial w/1 agent) or (‘‘anti-
bacterial’’ w/1 agent) or (bacteriocidal w/1 agent) or (antimycobacterial w/1 agents) or (‘‘anti-mycobacterial’’ w/1 agents) or (antibacterial w/1 agents) or
(‘‘anti-bacterial’’ w/1 agents) or (bacteriocidal w/1 agents))
3 1 and 2
4 TITLE-ABS-KEY(‘‘comparative study’’ OR ‘‘comparative survey’’ OR ‘‘comparative analysis’’ OR ‘‘cohort study’’ OR ‘‘cohort survey’’ OR ‘‘cohort analysis’’ OR
‘‘longitudinal study’’ OR ‘‘longitudinal survey’’ OR ‘‘longitudinal analysis’’ OR ‘‘retrospective study’’ OR ‘‘retrospective survey’’ or ‘‘retrospective analysis’’ OR
‘‘prospective study’’ OR ‘‘prospective survey’’ OR ‘‘prospective analysis’’ OR ‘‘concurrent study’’ OR ‘‘concurrent survey’’ OR ‘‘concurrent analysis’’ or ‘‘follow-up
study’’ OR ‘‘follow-up survey’’ OR ‘‘follow-up analysis’’ or ‘‘observational study’’ OR ‘‘observational survey’’ OR ‘‘observational analysis’’ OR ‘‘clinical study’’ OR
‘‘clinical trial’’ or ‘‘evaluation study’’ OR ‘‘evaluation survey’’ OR ‘‘evaluation analysis’’ or ‘‘validation study’’ OR ‘‘validation survey’’ OR ‘‘validation analysis’’)
5 TITLE-ABS-KEY((evidence W/1 based) OR (meta W/1 analys*) OR (systematic* W/2 review*) OR guideline OR (control* W/2 stud*) OR (control* W/2 trial*) OR
(randomized W/2 stud*) OR (randomized W/2 trial*))
6 3 and (4 or 5)
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Table 2 (Continued )
Scopus
7 PMID(0*) OR PMID(1*) OR PMID(2*) OR PMID(3*) OR PMID(4*) OR PMID(5*) OR PMID(6*)
OR PMID(7*) OR PMID(8*) OR PMID(9*)
8 6 and not 7
9 DOCTYPE(le) OR DOCTYPE(ed) OR DOCTYPE(bk) OR DOCTYPE(er) OR DOCTYPE(no) OR DOCTYPE(sh)
10 8 and not 9
LILACS
1 Bartonellosis or bartonellaceae OR rochalimaea OR oroya or Bartonella or Carrion disease or Carrion’s disease or Carrions disease or verruga peruana or
bacillary angiomatosis or trench fever [Words]
G. Prutsky et al. / International Journal of Infectious Diseases 17 (2013) e811–e819e814effect model and presented results for both. The analyses were
performed using Comprehensive Meta-Analysis (CMA) version 2.2
(Biostat Inc., Englewood, NJ, USA). Data were insufﬁcient to
perform the pre-speciﬁed subgroup analysis (based on immunity
status, risk of bias, and length of treatment). Evaluation of
publication bias was not feasible due to heterogeneity and the
small number of included studies.22
3. Results
3.1. Search results and study description
The literature search identiﬁed 157 articles, of which nine
studies met our eligibility criteria. Two were RCTs; one of them
evaluated24 adult patients with CSD and the other25 enrolled adult
patients with chronic bacteremia caused by B. quintana. Seven
retrospective cohort studies were included in this review; three of
them evaluated CSD26–28 and the other four evaluated chronic B.
quintana bacteremia,29 Carrion’s disease,14 bacillary angiomatosisFigure 1. Selection process due to B. henselae and B. quintana,30 and infectious endocarditis due
to B. henselae and B. quintana31 (Figure 1).
This review included 751 patients and their mean age was 29.46
years (range 6 months to 72 years). Most of the studies (n = 6) did
not report the length of the follow-up. Only one study30 evaluated
immunosuppressed patients (patients with HIV who developed
bacillary angiomatosis). Table 3 shows the characteristics of the
included trials.
3.2. Author contact
We attempted to contact two authors by e-mail14,29 in order to
clarify certain characteristics of their trials. We received one
answer.
3.3. Risk of bias
Both of the RCTs had adequate randomization methods, but the
allocation was not concealed in one of them and it was notof the included studies.
Table 3
Study characteristics
Study design n Age, years
(mean)
Bacterium/
disease
Patient characteristics,
diagnostic criteria, case deﬁnition
Follow-up (months) Intervention and length
of the intervention
Control
Bass 1998
RCT
35 19 B. henselae
CSD
Active duty military members and their dependents with
laboratory-conﬁrmed, clinically typical CSD
Patient with regional lymphadenopathy and a cat scratch/bite or
papule distal to the lymph nodes. In patients with regional
lymphadenopathy and no skin lesions, a history of intimate
contact with a cat that frequently scratched, bit, or licked
Around 2 months:
until the initial total
lymph node volume
has resolved to 20%
of that observed at
initiation of therapy
Azithromycin
5 days
Placebo
Foucault 2003
RCT
20 54 B. quintana
Chronic bacteremia
Patients >18 years old with a positive blood culture for
B. quintana
3 months Gentamicin + doxycycline
Mean: 28 days
No treatment
Arisoy 1999
Retrospective cohort
19 6.9 B. henselae
Hepato-splenic CSD
Evidence of hepatic and/or splenic lesions consistent with CSD:
ultrasound examination or CT; serological ﬁndings consistent
with CSD; and serology, cultures, and skin tests negative for
other likely causes of the illness
NR: until the onset
of clinical abatement
of the patient’s
presenting symptoms
and disappearance
of fever
Gentamicin, TMP–SMX,
rifampin, rifampin
+ gentamicin, rifampin +
TMP–SMX
8–17 days
NA
Collio 1992
Retrospective cohort
101 <17 B. henselae
CSD
Pediatric patients who were diagnosed with CSD in a pediatric
ofﬁce in Georgia. CSD lymphadenitis, regional lymphadenopathy
and adenitis diagnosed according to clinical history
NR: until the
problem was solved
TMP–SMX, cephalexin,
erythromycin, cloxacillin,
amoxicillin and clavulanate,
cefaclor
7–16 days
No treatment
Foucault 2002
Retrospective cohort
42 NR B. quintana
Chronic
bacteremia
Homeless people who presented to the emergency departments
and those who were admitted to medical facilities in city shelters
who had positive blood culture
NR: until 1 week after
the last blood culture
b-lactams, doxycycline,
doxycycline + rifampin
7–28 days
No treatment
Margileth 1992
Retrospective cohort
268 20 B. henselae
CSD
Adult and pediatric patients with CSD who were seen or
reported to the authors.
Patients had to meet four criteria: (1) history of cat contact and
presence of scratch or primary dermal, eye or mucosal contact,
(2) positive skin test, (3) negative studies for other causes of
lymphadenopathy, (4) characteristic biopsy
NR Antibiotic therapy (TMP–SMX,
ciproﬂoxacin, gentamicin
and rifampin)
Mean: 19.6 days
No treatment
Maguina 2001
Retrospective cohort
68 15 B. bacilliformis
Carrion’s disease
Peruvian patients, 59% were
natives from areas where
bartonellosis was endemic
and 41% were visitors to
such areas
Acute phase: at least one clinical
manifestation associated with the
acute phase and either a
positive
blood smear or a positive culture
for B. bacilliformis (blood or
bone marrow)
NR: until the resolution
of the disease or death
CAF, CAF + other, ampicillin,
norﬂoxacin
10–14 days
No treatment
77 18 Eruptive phase: clinical
manifestations and characteristic
ﬁndings on biopsy of one of
the lesions
Streptomycin or rifampin
10–14 days
NA
Plettenberg 2000
Retrospective cohort
20 39 B. henselae and
B. quintana
BA
Patients with HIV who developed bacillary angiomatosis.
Typical clinical manifestations and histological ﬁndings or
identiﬁcation of the bacteria by molecular biological techniques
NR: until the
resolution of the
disease or death
Erythromycin, doxycycline,
cefuroxime, imipenem
NR
NA
Raoult 2003
Retrospective cohort
49 51 B. quintana
IE
Adult patients, mainly men, who were diagnosed with
endocarditis. Dukes criteria + positive culture, DNA
ampliﬁcation from valvular tissue or blood, or when
patients had IgG titers 1/800
NR b-lactams, b-
lactams + aminoglycosides,
rifampin  other, aminoglycosides
 other, doxycycline  other
non-aminoglycoside, doxycycline
 other, ﬂuoroquinolone  other
NR
NA
12 B. henselae
IE
BA, bacillary angiomatosis; CAF, chloramphenicol; CSD, cat scratch disease; CT, computed tomography; IE, infectious endocarditis; NA, not applicable,; NR, not reported; RCT, randomized controlled trial; TMP–SMX, trimethoprim–
sulfamethoxazole.
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G. Prutsky et al. / International Journal of Infectious Diseases 17 (2013) e811–e819e816reported in the other. One was an open label study and the other
was double-blinded. Both of them reported an important attrition
during follow-up – 17% and 20%.
The overall risk of bias in this body of evidence was considered
high, since the RCTs had a high rate of loss to follow-up and no clear
allocation concealment and the non-RCTs were retrospective with
small sample sizes (the largest sample size was 268 patients).
Table 4 describes the quality of the included studies.
3.4. Outcomes of interest
3.4.1. Cat scratch disease
We found two studies that evaluated antibiotic therapy in CSD.
The ﬁrst was an RCT comparing azithromycin to placebo, and the
second was a non-randomized observational study comparing
trimethoprim–sulfamethoxazole (TMP–SMX), ciproﬂoxacin, gen-
tamicin, and rifampin to no treatment. A meta-analysis of these
two studies did not show a statistically signiﬁcant effect in terms of
cure rate (all patients in both arms were cured, 130 patients in two
included studies) or time to achieve cure (WMD 1.49 days, 95% CI
9.38 to 12.35, p = 0.79, I2 = 23%) (Figure 2). A third study
evaluated 19 patients with a prolonged duration of fever (3
weeks) due to hepatosplenic CSD26 and found that the patients
who received rifampin alone or in combination improved after 1–5
days of treatment, and patients who received other treatments
(gentamicin or TMP–SMX) improved after 3–4 days. Interestingly,
azithromycin, the current recommended treatment16 was only
evaluated in one study.Figure 3. Forrest plot: C
Figure 2. Forrest plot: C3.4.2. Carrion’s disease
One observational study14 evaluated both phases of Carrion’s
disease, but only data for the eruptive phase, verruga peruana,
were available. The authors reported the response rate by day 10 of
treatment as ‘good’, ‘fair’, and ‘poor’, when the reduction in lesion
size and improvement in color was 90%, 50–90%, and <50%,
respectively. The study compared the use of rifampin vs.
streptomycin; there was no statistically signiﬁcant difference in
the achievement of a good response (OR 0.30, 95% CI 0.07–1.37,
p = 0.12).
3.4.3. Chronic bacteremia
Using the pooled data from two studies (one RCT and one
observational study), the use of gentamicin and doxycycline
showed a statistically signiﬁcant increase in the resolution rate of
chronic bacteremia compared with no treatment (OR 15.90, 95% CI
2.68–94.53, p = 0.02, I2 = 0) (Figure 3). An RCT showed an increase
in the time to achieve cure compared to no treatment (reported
only in one RCT; WMD 8.50 days, 95% CI 2.76–14.24, p = 0.004).
3.4.4. Bacillary angiomatosis
One of the observational studies evaluated bacillary angioma-
tosis30 in patients with HIV. The study did not show a statistically
signiﬁcant difference between the use of erythromycin and
doxycycline in terms of cure rate (OR 6.50, 95% CI 0.28–151.123,
p = 0.24) or relapse rate (OR 1.96, 95% CI 0.08–48.26, p = 0.68).
Compared with amoxicillin–clavulanate, cefuroxime, or imipe-
nem, erythromycin showed a statistically signiﬁcant difference inhronic bacteremia.
at scratch disease.
Table 4
Quality assessment
Randomized controlled trials
Study Blinding Randomization method Allocation
concealment
Lost to follow-up Base-line
imbalances
Efﬁcacy follow-up Adherence follow-up Source of funding
Bass 1998 Care givers,
patients
Table of
random numbers
NR 17.14% No All study subjects were
reevaluated clinically
and by repeat ultrasonography studies
The administration of
several doses was
supervised
NR
Foucault
2003
Open label Prepared blocks
of envelopes
No 20% No Patients in the treatment
group were hospitalized for the ﬁrst
14 days for treatment. For the remaining
14 days patients received their treatment
either in the hospital or in medical facilities
Patients in the treatment
arm were hospitalized and
untreated controls were
monitored either in the
hospital or in medical
facilities of the city shelters
NFP
Observational studies
Study Selection Comparability Outcome Source of funding
Representative
of exposed,
selection of
the non-exposed
Ascertainment
of exposure
Outcome
was not present
at the beginning
Comparability of cohorts Similar assessment Was follow-up
long enough?
Non-response rate
Arisoy 1999 Patients treated in a
tertiary care center. All the
participants came from the
same center
Yes Yes Same community and same
management
Yes, quite similar Yes 0% NR
Collio 1992 Patients with mild disease.
All the participants came
from the same center
Yes Yes Same community and same
management
Yes, quite similar Yes 0% NR
Foucault 2002 Homeless people. All the
participants came from the
same center
Yes Yes Same community and same
management
Yes, quite similar Not clear 14% NFP
Margileth 2002 Unclear NR Yes Same community and same
management
Yes, quite similar Not clear 0% NR
Maguina 2001 Patients of both genders,
wide range of ages. All the
participants came from the
same center
Yes Yes Same community and same
management
Yes, quite similar Yes 0% NR
Plettenberg 2000 HIV patients. All the
participants came from the
community
Yes Yes Same community and same
management
Yes, quite similar Yes 0% NR
Raoult 2003 Patients with high risk
factors. All the participants
came from the same
community
Yes Yes Same community and same
management
Yes, quite similar Not clear 0% NR
NFP, not for proﬁt; NR, not reported.
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rate (OR 0.06, 95% CI 0.002–1.31, p = 0.07); doxycycline did not
show a statistically signiﬁcant difference in cure rate (OR 7.00, 95%
CI 1.168–291.34, p = 0.306) or relapse rate (OR 0.029, 95% CI 0.000–
1.99, p = 0.1) when compared with the same treatments.
We did not ﬁnd any studies meeting our criteria that evaluated
patients with peliosis hepatis.
3.4.5. Infectious endocarditis
Infectious endocarditis caused by B. henselae or B. quintana was
reported in one observational study.31 The recommended treat-
ment for this disease includes gentamicin and ceftriaxone with or
without doxycycline;16 hence we considered aminoglycoside + b-
lactams as the intervention of interest. This combination was not
statistically more effective than other antibiotic treatment (b-
lactams alone, such as amoxicillin, ceftriaxone, benzylpenicillin,
and oxacillin; rifampin  other, aminoglycosides  other, doxycy-
cline  other non-aminoglycoside, and ﬂuoroquinolones  other) in
cure rate (OR 1.55, 95% CI 0.66–3.63, p = 0.31), death rate (OR 0.78,
95% CI 0.33–1.86, p = 0.58), or relapse rate (OR 0.20, 95% CI 0.01–3.74,
p = 0.58).
4. Discussion
We conducted a systematic review and meta-analyses to
determine the efﬁcacy of different antibiotic regimens in the
treatment of infection caused by the three most common species of
human Bartonella (B. henselae, B. quintana, and B. bacilliformis).
4.1. Main ﬁndings
4.1.1. Cat scratch disease
The available data do not support the use of antibiotics for the
management of CSD. No particular antibiotic regimen was shown
to be beneﬁcial in improving the cure rate or time to achieve cure.
Therefore, the unknown beneﬁt with the potential for adverse
effects limits the recommendation of a preferred approach.
Considering the severity of the potential sequelae of the
systemic disease (hepatosplenic disease, neuroretinitis, neurologic
disease), it is quite concerning that that there is no available
evidence for treatment efﬁcacy, safety, or prevention of disease. It
remains unclear whether the antibiotic treatment of a localized
disease reduces the risk of the development of a systemic disease.
Well designed and conducted RCTs evaluating the beneﬁts and
harms of azithromycin, currently recommended as the therapy of
choice, are needed.16
4.1.2. Carrion’s disease
The disease is characterized by an initial febrile or hematic
phase known as Oroya fever; if untreated it may have a mortality
risk higher than 40%.8 Currently the recommended treatment
includes chloramphenicol or ciproﬂoxacin.16 Considering the high
mortality risk, the lack of evidence to support any of these
treatments is concerning.
For the second (eruptive) phase of the disease, also known as
verruga peruana, the recommended treatment is rifampin or
streptomycin, and our meta-analysis showed that there is no
difference between them. However, the evidence to support their
beneﬁts over other therapies, even in guidelines, is weak16 and
sometimes contradictory with microbiological research.32
4.1.3. Chronic bacteremia
The meta-analysis demonstrated that the treatment of patients
with chronic bacteremia (caused by B. henselae and/or B. quintana)
with gentamicin and doxycycline, in accordance with the current
recommendation,16 increases the cure rate. However, thetreatment effect was only evaluated by a negative blood
culture and not by clinical symptomatology, clinical deterioration,
and development of endocarditis or mortality. Having
evidence measuring the impact on these clinically important
outcomes would be more important from a patient point of
view and provide a rationale for the current recommendations.
4.1.4. Bacillary angiomatosis
The only study that involved immunocompromised patients
included in this review evaluated bacillary angiomatosis in HIV
patients. The study showed that erythromycin might be better
than other antibiotics, but with no statistically signiﬁcant
difference from doxycycline.
4.1.5. Infectious endocarditis
The incidence of this complication is low; however endocarditis
caused by these pathogens can lead to signiﬁcant morbidity due to
large valvular vegetations and embolic phenomena requiring valve
replacement.33 The need for antibiotics in this presentation is clear,
but the current recommended regimen (gentamicin and ceftriax-
one with or without doxycycline16) was not better than other
combinations.
In general, the available evidence for all the evaluated
syndromes and antibiotic combinations is of low quality due to
the high risk of bias and imprecision (Figure 3).
4.2. Limitations and strengths
The quality of the evidence presented in this review is very low
due to the small number of studies, low quality, high rates of loss to
follow-up in the RCTs, heterogeneity, and imprecision (small
sample size and wide conﬁdence intervals).
The strength of this review relates to the comprehensive
nature of the literature search and the inclusion of 10 non-
indexed journals, increasing the sensitivity of the search
strategy. We also followed several measures to reduce the
effect of bias such as establishing a predeﬁned protocol,
duplicate study selection, and attempting to contact the authors
of the included studies.
Although there is no standardized method for the diagnosis of
these diseases most of the included studies used microbiological
evidence for the diagnosis of the infection. We consider this the
ideal method for the diagnosis of an infection caused by Bartonella
spp.
4.3. Implications for practice
In some of the Bartonella syndromes known to have a high
mortality, or in complications such as bacillary angiomatosis,
infectious endocarditis, or Oroya fever, antibiotic treatment
should be provided empirically. The comparative effectiveness
evidence is insufﬁcient to allow the favoring of one of these
regimens over another. In other Bartonella syndromes such as
CSD, withholding antibiotics should be evaluated on an individual
basis since evidence of beneﬁt that exceeds adverse effects is
unavailable.
5. Conclusions
This review demonstrates that the current clinical practice for
the treatment of immunocompetent and immunosuppressed
patients with Bartonella infections relies mostly on personal
experience, expert opinion, and microbiological susceptibility
data. Randomized trials are needed in the ﬁeld to compare
different treatment options.
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